Navigation Links
Elbit Imaging Ltd. Announces Interest Rate for the Next Interest Period for Series B Notes
Date:8/23/2011

TEL AVIV, Israel, August 23, 2011 /PRNewswire/ --

Elbit Imaging Ltd. ("EI" or the "Company") (NASDAQ: EMITF), announced today, in accordance with Section 4 of the "Terms Behind the Page" of Series B Notes of the Company, that the interest rate borne by Series B Notes for the interest period beginning on August 21, 2011 and ending on February 21, 2012 is 1.56055%.

About Elbit Imaging Ltd.

Elbit Imaging Ltd. operates in the following principal fields of business: (i) Commercial and Entertainment Centers - Initiation, construction and sale of shopping and entertainment centers and other mixed-use real property projects, predominantly in the retail sector, located in Central and Eastern Europe and in India; (ii) U.S. Real Property - Investment in commercial real property in the United States; (iii) Hotels - Hotel operation and management, primarily in major European cities; (iv) Medical Industries - (a) research and development, production and marketing of magnetic resonance imaging guided focused ultrasound treatment equipment and (b) development of stem cell population expansion technologies and stem cell therapy products for transplantation and regenerative medicine; (v) Residential Projects - Initiation, construction and sale of residential projects and other mixed-use real property projects, predominately residential, located primarily in India and in Eastern Europe; (vi) Fashion Apparel - Distribution and marketing of fashion apparel and accessories in Israel; and (vii) Other Activities - (a) venture capital investments and (b) investments in hospitals and farm and dairy plants in India. We have presently decided to suspend our investment activities in hospitals and farm and dairy plants in India until we are satisfied that the economy has recovered sufficiently to resume such activities.

Any forward-looking statements in our releases include statements regarding the intent, belief or current expectations of Elbit Imaging Ltd. and our management about our business, financial condition, results of operations, and its relationship with its employees and the condition of our properties. Words such as "believe," "expect," "intend," "estimate" and similar expressions are intended to identify forward-looking statements but are not the exclusive means of identifying such statements. Actual results may differ materially from those projected, expressed or implied in the forward-looking statements as a result of various factors including, without limitation, the factors set forth in our filings with the Securities and Exchange Commission including, without limitation, Item 3.D of our annual report on Form 20-F for the fiscal year ended December 31, 2010, under the caption "Risk Factors." Any forward-looking statements contained in our releases speak only as of the date of such release, and we caution existing and prospective investors not to place undue reliance on such statements. Such forward-looking statements do not purport to be predictions of future events or circumstances, and therefore, there can be no assurance that any forward-looking statement contained our releases will prove to be accurate. We undertake no obligation to update or revise any forward-looking statements.


For Further Information:


    
    Company Contact:
    Dudi Machluf
    Chief Executive Officer (Co-CEO)
    Tel: +972-3-608-6024
    dudim@elbitimaging.com 

    
    Investor Contact:
    Mor Dagan
    Investor Relations
    Tel: +972-3-516-7620
    mor@km-ir.co.il
 



'/>"/>
SOURCE Elbit Imaging Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Elbit Imaging Announces Share Purchase Agreement With Enter Holdings
2. Elbit Imaging Announces Insightec Treats First Prostate Cancer Patients in Clinical Trials
3. Elbit Imaging Ltd. Announces First Quarter Results for 2010
4. Elbit Imaging Announces Data Monitoring Committee Recommends Continuation of Phase III Study of StemEx(R), a Cord Blood Stem Cell Product, for Leukemia and Lymphoma
5. Elbit Imaging Announces InSightecs First Non-Invasive Technology for Treatment of Uterine Fibroids Awarded MHLW Approval in Japan
6. Elbit Imaging Ltd. Announces Sale of Plaza Centers Shares
7. Elbit Imaging Ltd. Announces - Swiss Team Uses InSightecs ExAblate(R) 4000 Brain System to Treat Patients With Functional Brain Disorders
8. Pathologists Gather to Focus on Advances in Molecular Testing, Digital Imaging, and Biospecimens
9. Strategic Assessments of Leading North American Diagnostic Imaging Market Players
10. MarketsandMarkets: "Radiopharmaceuticals for Therapy and PET/SPECT Imaging" Market to reach $4,734 Million by 2015
11. Unrestricted Access to Advanced Imaging a Top Priority for Consumers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... Mass. , April 20, 2017  RXi ... developing innovative therapeutics that address significant unmet medical ... data from the Company,s consumer product development program, ... at the Society for Investigative Dermatology (SID) 76 ... to advance and promote the sciences relevant to ...
(Date:4/20/2017)... -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today ... C virus (HCV) infected patients with genotype 1, ... (Child-Pugh A) achieved sustained virologic response at 12 ... pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). These high SVR ... of G/P treatment without ribavirin. Patients with specific ...
(Date:4/20/2017)... Research and Markets has announced the addition of ... By Service (Manufacturing, Research), By Country, (Brazil, Mexico, Colombia, Argentina, ... to their offering. ... The Latin American pharmaceutical contract manufacturing services market is anticipated ... drug registration cost in Latin American countries and continuous economic ...
Breaking Medicine Technology:
(Date:4/24/2017)... ... April 24, 2017 , ... Ridgecrest Herbals makes it a point to lead ... reduce waste, and support renewable energy. They believe this is a crucial part of ... solutions for health issues, and maintain that destroying the environment in the pursuit of ...
(Date:4/24/2017)... ... ... , a national non-profit organization focusing on the prevention and early detection of breast and ... to announce Katie Thiede as their new Chief Executive Officer. In January, founder Lindsay Avner ... Board and launched a national search to find a visionary new leader to grow Bright ...
(Date:4/24/2017)... ... April 24, 2017 , ... The John P. McGovern Museum of Health and ... to track their cognitive health, and share results with their physicians. Members and guests ... the museum's website. , BrainCheck founder, Dr. David Eagleman, formerly at Baylor College of ...
(Date:4/24/2017)... , ... April 24, 2017 , ... ... within the telehealth industry, announces the company’s VideoMedicine mobile platform has launched Quick ... Available 24 hours a day, Quick Care provides patients with the option to ...
(Date:4/24/2017)... ... April 24, 2017 , ... MAP Health Management announced today ... people with addiction who are served by MAP’s patient engagement ecosystem. Lief Therapeutics ... monitors heart and breath rates to identify anxiety levels and can provide biofeedback ...
Breaking Medicine News(10 mins):